Recent News

• 06.13.2025 - Quantum BioPharma Announces Intention to Declare Special Dividend of Contingent Value Rights (CVRs) Linked to Future Litigation Settlement Proceeds
• 06.10.2025 - Quantum Biopharma Purchases More Bitcoin (BTC) Bringing the Total Investment in Digital Assets to USD $5,000,000
• 06.03.2025 - Quantum BioPharma Clarifies It Has Not Changed Its Name
• 05.30.2025 - Quantum BioPharma Receives $2.35 Million USD from a Mutually-Agreed Global Legal Settlement with Dr. Raza Bokhari
• 05.29.2025 - Quantum Biopharma Licensee Celly Nutrition Retains Leading Audit Firm MNP LLP to Advance Capital Raise and Go-Public Readiness and Changes Name To Unbuzzd Wellness Inc.
• 05.28.2025 - Quantum BioPharma Receives Ethics Committee Approval for Phase 2 Clinical Trial of FSD202 for Nociplastic Pain in Patients with Idiopathic Mast Cell Activation Syndrome

Recent Filings

• 06.13.2025 - EX-99.1 EX-99.1
• 06.13.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 06.12.2025 - SCHEDULE 13D General Statement of Acquisition of Beneficial Ownership
• 06.11.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 06.10.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 06.10.2025 - EX-99.1 EX-99.1
• 06.03.2025 - EX-99.1 EX-99.1
• 06.03.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 05.30.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 05.30.2025 - EX-99.1 EX-99.1